| |
[SORT BY TITLE] [SORT BY DATE] [SORT BY AUTHOR]
FDA Reform
- Supreme Court Drug Decisions Are Blows For Common Sense By James R. Copland, Washington Examiner, 06-30-11
- Why Does FDA Keep Drugmakers From Informing Doctors? By James R. Copland, Investor's Business Daily, 01-09-13
- In the Wake of Wyeth v. Levine: Making the Case for FDA Preemption and Administrative Compensation James R. Copland, Project FDA Report, March 2009
- Richard Epstein explains why the FDA should not fear conflicts-of-interest and gives his solutions for the dilemma. Richard A. Epstein, Podcast: Interview, October 19, 2010
- Unshackle the FDA From Rules That Kill Innovation By Richard A. Epstein, Forbes.com, 03-15-12
- Causing More Harm than Good: Conflict-of-Interest Rules Thwart Medical Progress By Richard A. Epstein, Forbes.com, 10-26-10
- Do You Know Where Your Food Comes From? By Diana Furchtgott-Roth, RealClearMarkets, 02-19-09
- Prescription for Progress: The Critical Path To Drug Development Robert M. Goldberg, Medical Progress Report, June 2006
- Making the FDA More Patient-Friendly David Gratzer, Blog Post, 06-16-10
- 'Caution Syndrome' Infects The FDA By David Gratzer, Forbes.com, 05-21-09
- The Right Way to Stop Superbugs By David Gratzer, New York Post, 11-12-10
- The Cure: How Capitalism Can Save American Health Care David Gratzer, Book, October 2006
- About the FDA's New Calorie Count Regulations By David Gratzer, The Weekly Standard, 04-06-11
- CBO: Cutting the Fat Will Cut Costs David Gratzer, Blog Post, 09-15-10
- The right prescription for drug safety By Marie Gryphon, Washington Examiner, 12-04-08
- How To Liberate New Frontier Of Modern American Medicine By Douglas Holtz-Eakin, Investor's Business Daily, 11-09-11
- The Way Forward On Health Care, And No, It's Not Obamacare By Douglas Holtz-Eakin, FoxNews.com, 09-29-10
- High-Priced Cancer Drugs: Are They Worth It? By Paul Howard, National Review Online, 07-08-11
- Cancer Revolution Is Possible With More Flexible FDA By Paul Howard, Washington Examiner, 06-09-11
- Paul Howard interviews Jeffrey Kasher about Lilly's involvement in TransCelerate BioPharma, an industry-wide collaboration that is aimed at developing shared research solutions to accelerate the deliv Paul Howard, Podcast: Interview, October 8, 2012
- Improving the FDA By Paul Howard, Washington Examiner, 05-24-12
- Paul Howard and Alex Tabarrok discuss the recent surge in drug shortages and what the U.S. can do to bring more drugs to market Paul Howard, Podcast: Interview, April 4, 2012
- The right prescription for drug safety By Paul Howard, Washington Examiner, 12-04-08
- The End of the Age of Lipitor? You'd Better Hope Not. By Paul Howard, Medical Progress Today, 11-30-11
- Don't Forget About the FDA By Paul Howard, National Review Online, 08-12-11
- Why Does FDA Keep Drugmakers From Informing Doctors? By Paul Howard, Investor's Business Daily, 01-09-13
- Paul Howard and Avik Roy discuss findings from the American Society of Clinical Oncology conference and what is driving cancer innovation forward. Paul Howard, Podcast: Interview, June 7, 2012
- In the Wake of Wyeth v. Levine: Making the Case for FDA Preemption and Administrative Compensation Paul Howard, Project FDA Report, March 2009
- Innovation, Not Spending Cuts, Improves Health Care By Paul Howard, Investor's Business Daily, 01-04-12
- Renewing User-Fee Program Will Boost Innovation, FDA Performance By Paul Howard, Washington Examiner, 11-03-11
- Paul Howard interviews Josh Bloom, director, chemical and pharmaceutical sciences, American Council on Health and Science, about his MedicalProgressToday.com article, "Qsymia is Not Fen-Phen." Paul Howard, Podcast: Interview, July 25, 2012
- Richard Epstein explains why the FDA should not fear conflicts-of-interest and gives his solutions for the dilemma. Paul Howard, Podcast: Interview, October 19, 2010
- Gates Invests Time, Cash Into Drug Research By Paul Howard, Washington Examiner, 11-25-11
- Paul Howard interviews Marc M. Boutin, about PEDUFA and why the FDA needs to re-evaluate the way it approves drugs and medical devices. Paul Howard, Podcast: Interview, July 21, 2011
- Why We Need an FDA 2.0 By Paul Howard, National Review Online, 06-24-11
- Expensive Innovation Is Only Path To Cheap Lipitor By Paul Howard, Washington Times, 12-22-11
- Former Obama Adviser Warns of the Perils of Price Controls By Paul Howard, National Review Online, 08-17-11
- The Real Problem With Withdrawing Avastin By Paul Howard, Health Affairs, 01-19-11
- The Way Forward On Health Care, And No, It's Not Obamacare By Paul Howard, FoxNews.com, 09-29-10
- Market Better Than FDA To Address Drug Shortages By Paul Howard, Washington Examiner, 03-01-12
- Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research Tomas J. Philipson, Project FDA Report, June 2011
- Cost of Caution: The Impact on Patients of Delayed Drug Approvals Tomas J. Philipson, Project FDA Report, June 2010
- Quantifying High Cost Of Caution May Speed Drug Approval Process By Tomas J. Philipson, Investor's Business Daily, 06-14-10
- Sens. Richard Burr and Tom Coburn Introduce a New Plan to Reform the FDA By Avik Roy, Forbes.com, 04-18-12
- Market-Oriented Medicare Advantage is Especially Popular in Big Swing States By Avik Roy, National Review Online, 04-24-12
- Paul Howard and Avik Roy discuss findings from the American Society of Clinical Oncology conference and what is driving cancer innovation forward. Avik Roy, Podcast: Interview, June 7, 2012
- How the FDA Stifles New Cures, Part I & II By Avik Roy, Forbes.com, 04-25-12
- Cost of Caution: The Impact on Patients of Delayed Drug Approvals Eric Sun, Project FDA Report, June 2010
- Quantifying High Cost Of Caution May Speed Drug Approval Process By Eric Sun, Investor's Business Daily, 06-14-10
- Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research Eric Sun, Project FDA Report, June 2011
- Toward a 21st-Century FDA By Dr. Andrew von Eschenbach, Wall Street Journal, 04-15-12
- FDA Approvals Are a Matter of Life and Death By Dr. Andrew von Eschenbach, Wall Street Journal, 06-17-12
- The Bureaucratization of Safety and Effectiveness By Dr. Benjamin Zycher, Medical Progress Today, 07-07-06
|
|
|
